Patents by Inventor James Myette

James Myette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • High mannose glycans
    Patent number: 9921210
    Abstract: Methods and compositions related to high mannose glycans are described.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: March 20, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Brian Edward Collins, Jay Duffner, Carlos J. Bosques, Dorota A. Bulik, James Myette, James Meador
  • Antibody molecules to dengue virus and uses thereof
    Patent number: 9365639
    Abstract: Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: June 14, 2016
    Assignee: VISTERRA, INC.
    Inventors: Luke Robinson, Zachary Shriver, James Myette, Gregory Babcock, Karthik Viswanathan
  • ANTIBODY MOLECULES TO DENGUE VIRUS AND USES THEREOF
    Publication number: 20160046697
    Abstract: Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.
    Type: Application
    Filed: October 23, 2015
    Publication date: February 18, 2016
    Inventors: Luke Robinson, Zachary Shriver, James Myette, Gregory Babcock, Karthik Viswanathan
  • Antibody molecules to dengue virus and uses thereof
    Patent number: 9212217
    Abstract: Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: December 15, 2015
    Assignee: Visterra, Inc.
    Inventors: Luke Robinson, Zachary Shriver, James Myette, Gregory Babcock, Karthik Viswanathan
  • ANTIBODY MOLECULES TO DENGUE VIRUS AND USES THEREOF
    Publication number: 20150225474
    Abstract: Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.
    Type: Application
    Filed: January 20, 2015
    Publication date: August 13, 2015
    Inventors: Luke Robinson, Zachary Shriver, James Myette, Gregory Babcock
  • HIGH MANNOSE GLYCANS
    Publication number: 20130231255
    Abstract: Methods and compositions related to high mannose glycans are described.
    Type: Application
    Filed: April 7, 2011
    Publication date: September 5, 2013
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Brian Edward Collins, Jay Duffner, Carlos J. Bosques, Dorota A. Bulik, James Myette, James Meador
  • Heparan sulfate glycosaminoglycan lyase and uses thereof
    Patent number: 8198050
    Abstract: The invention provides recombinant B. thetaiotaomicron GAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron GAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: June 12, 2012
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: James Myette
  • HEPARAN SULFATE GLYCOSAMINOGLYCAN LYASE AND USES THEREOF
    Publication number: 20110104814
    Abstract: The invention provides recombinant B. thetaiotaomicron GAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron GAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: December 21, 2010
    Publication date: May 5, 2011
    Inventor: James Myette
  • Heparan sulfate glycosaminoglycan lyase and uses thereof
    Patent number: 7888072
    Abstract: The invention provides recombinant B. thetaiotaomicron GAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron GAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: February 15, 2011
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: James Myette
  • Heparan sulfate glycosaminoglycan lyase and uses thereof
    Patent number: 7767420
    Abstract: The invention provides recombinant B. thetaiotaomicron HSGAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron HSGAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: August 3, 2010
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: James Myette
  • Glycosaminoglycan lyase IV and uses thereof
    Patent number: 7691613
    Abstract: The invention provides recombinant B. thetaiotaomicron GAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron GAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: April 6, 2010
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: James Myette
  • Heparan sulfate glycosaminoglycan lyase and uses thereof
    Patent number: 7691612
    Abstract: The invention provides recombinant B. thetaiotaomicron GAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron GAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: April 6, 2010
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: James Myette
  • HEPARAN SULFATE GLYCOSAMINOGLYCAN LYASE AND USES THEREOF
    Publication number: 20090298157
    Abstract: The invention provides recombinant B. thetaiotaomicron GAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron GAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 6, 2009
    Publication date: December 3, 2009
    Inventor: James Myette
  • 2-O sulfatase compositions and methods of degradation therewith
    Patent number: 7504247
    Abstract: The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: March 17, 2009
    Assignee: Massachusetts Institute of Technology
    Inventors: Ram Sasisekharan, James Myette, Zachary Shriver, Ganesh Venkataraman
  • Heparan Sulfate Glycosaminoglycan Lyase and Uses Thereof
    Publication number: 20080171367
    Abstract: The invention provides recombinant B. thetaiotaomicron GAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron GAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: November 30, 2007
    Publication date: July 17, 2008
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventor: James Myette
  • Heparan Sulfate Glycosaminoglycan Lyase and Uses Thereof
    Publication number: 20080171375
    Abstract: The invention provides recombinant B. thetaiotaomicron HSGAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron HSGAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: November 29, 2007
    Publication date: July 17, 2008
    Inventor: James Myette
  • 2-O sulfatase nucleic acid compositions
    Patent number: 7396824
    Abstract: The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: July 8, 2008
    Assignee: Massachusetts Institute of Technology
    Inventors: Ram Sasisekharan, James Myette, Zachary Shriver, Ganesh Venkataraman
  • Heparan sulfate glycosaminoglycan lyase and uses thereof
    Publication number: 20070134226
    Abstract: The invention provides recombinant B. thetaiotaomicron GAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron GAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: November 3, 2006
    Publication date: June 14, 2007
    Inventor: James Myette
  • Heparan sulfate glycosaminoglycan lyase and uses thereof
    Publication number: 20070098708
    Abstract: The invention provides recombinant B. thetaiotaomicron HSGAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron HSGAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: November 3, 2005
    Publication date: May 3, 2007
    Inventor: James Myette
  • 2-O sulfatase compositions and methods of hydrolyzing therewith
    Publication number: 20070004012
    Abstract: The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.
    Type: Application
    Filed: May 11, 2006
    Publication date: January 4, 2007
    Applicant: Massachusetts Institute of Technology
    Inventors: Ram Sasisekharan, James Myette, Zachary Shriver, Ganesh Venkataraman